Cereno Scientific presented at Life Sciencedagen in Gothenburg, March 6

CEO Sten R. Sörensen and CMO and Head of R&D Rahul Agrawal, presented the company portfolio, the role of HDAC inhibition and disease-modifying properties of CS1 in PAH, gave an overview of thrombosis prevention with CS014, and an introduction to the preclinical program CS585.
 
See the full presentation here.